ETEiji Tanaka

Eiji Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eiji Tanaka has a total of 86 co-authors. Here are the top co-authors by number of shared publications:

  • Kendo Kiyosawa

    Department of Medicine, Shinshu University School of Medicine, Matsumoto

    14 shared publications
  • Akihiro Matsumoto

    Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

    7 shared publications
  • Kaname Yoshizawa

    Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

    7 shared publications
  • Akinori Rokuhara

    Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

    6 shared publications
  • Amal Gad

    Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

    5 shared publications
  • Koji Orii

    Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan

    4 shared publications

Latest Publications

  • Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody

    by Akihiro Matsumoto, Masayasu Imaizumi, Yasuhito Tanaka, Shuhei Nishiguchi, Hiroshi Yatsuhashi, Takehiko Ishida, Kazushige Moriyama, Katsumi Aoyagi, Eiji Tanaka

    Background Hepatitis B surface antigen (HBsAg) is used as a clinical marker of hepatitis B virus (HBV) infection. However, conventional HBsAg assays have so far failed to accurately detect HBsAg in blood because of interference by patient-derived antibodies against HBsAg (HBsAb). Methods We developed a novel, fully automated assay system that can detect total HBsAg in blood, including antigens complexed with HBsAb. The immunoassay inactivates HBsAb via a simple pretreatment step to dissociate the HBsAg molecule from HBsAg–HBsAb complexes and thereby estimate total HBsAg. Accordingly, the test has been termed the “immunoassay for total antigen including complex via pretreatment (iTACT)-HBsAg.” Results The recovery rate of HBsAg in the presence of HBsAb was greater than 87 % at a cutoff value set at 5.0 mIU/mL on the basis of data from 545 healthy controls. Analyses using serial serum samples from 25 HBV carriers who became negative for HBsAg during follow-up showed that the iTACT-HBsAg could detect HBsAg over a period of years despite a loss in detection by conventional assays and was able to detect HBsAg in 39 (53 %) of 73 samples with HBsAb. Conclusions The new iTACT-HBsAg assay appears to detect total HBsAg with high sensitivity, even in the presence of HBsAb, and may useful in identifying subclinical or occult HBV carriers.


  • Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy

    by Akihiro Matsumoto, Eiji Tanaka, Masahito Minami, Takeshi Okanoue, Hiroshi Yatsuhashi, Shinya Nagaoka, Fumitaka Suzuki, Mariko Kobayashi, Kazuaki Chayama, Michio Imamura, et al.

    Aim:  The clinical significance of hepatitis B virus (HBV) core‐related antigen (HBcrAg) in predicting the reactivation of hepatitis after halting lamivudine administration was analyzed.Methods:  A total of 34 patients with chronic hepatitis B were enrolled. Lamivudine was administered for at least 6 months before cessation, and reactivation of hepatitis was defined as elevation of alanine aminotransferase levels to more than 80 IU/L within 12 months of cessation.Results:  In total, 20 (59%) patients experienced hepatitis reactivation. Although concentrations of HBV DNA and HBcrAg in serum did not differ between the two groups of patients at the onset of lamivudine administration, HBcrAg serum levels were significantly higher (P = 0.009) in the reactivation patients (median 4.9, 25–75% range 4.7– 5.9 log unit/mL) than the non‐reactivation patients (median 3.2, 25–75% range Conclusion:  HBcrAg can be a useful marker to identify patients who are not at risk of reactivation of severe hepatitis after discontinuation of lamivudine administration.


  • Open Access

    Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics

    by Noriko Misawa, Akihiro Matsumoto, Eiji Tanaka, Akinori Rokuhara, Kaname Yoshizawa, Takeji Umemura, Noboru Maki, Tatsuji Kimura, Kendo Kiyosawa

    The characteristic differences between patients with and without loss of hepatitis B virus (HBV) DNA after achieving hepatitis B e antigen seroconversion were analyzed by comparing changes in HBV DNA and HBV core-related antigen levels during a period from 3 years before to 3 years after the seroconversion. Of the 24 seroconverters, 6 (inactive replication group) showed continuous loss of HBV DNA in serum after the seroconversion and the remaining 18 did not lose HBV DNA (active replication group). The HBV DNA level was similar between the two groups, while the HBV core-related antigen level was significantly lower in the active replication group than in the inactive replication group before the seroconversion. The levels of both HBV DNA and HBV core-related antigen decreased remarkably around the time of seroconversion in the inactive replication group, while these levels did not change or decreased slightly in the active replication group. After the seroconversion, the HBV DNA level was significantly higher in the active replication group than in the inactive replication group, while the HBV core-related antigen level was similarly low between the two groups. Because the serum level of HBV core-related antigen mainly reflects that of HBe antigen, the low level of HBV core-related antigen seen after seroconversion in both groups might have contributed to the occurrence of seroconversion. The precore and core promoter mutations which cause diminished excretion of hepatitis B e antigen were significantly more frequent in the active replication group than in the inactive replication group. It was therefore considered that the seroconversion was caused mainly by a decrease in viral replication in the inactive replication group, and mainly by a decrease in HBe antigen production in the active replication group. J. Med. Virol. 78:68–73, 2006.


  • Open Access

    Hepatitis B virus core and core‐related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection

    by Akinori Rokuhara, Xiaohong Sun, Eiji Tanaka, Tatsuji Kimura, Akihiro Matsumoto, Dongmei Yao, Lei Yin, NA Wang, Noboru Maki, Kendo Kiyosawa

    Background and Aims:  Hepatitis B virus (HBV) core‐related antigen (HBcrAg) and HBV core antigen (HBcAg) assays were developed for the measurement of serum HBV load. The aim of this study was to assess the clinical utility of these assays in Chinese patients with chronic genotype B and C HBV infection.Methods:  One hundred and ninety‐three chronic hepatitis B patients were enrolled. Serum HBcrAg and HBcAg were measured by chemiluminescence enzyme immunoassay, and HBV‐DNA was measured by using a sensitive polymerase chain reaction assay. The data were analyzed in patients with HBV genotype B (HBV/B) and genotype C (HBV/C). The HBcrAg/HBcAg ratio was calculated and compared between patients with and without hepatitis B e antigen (HBeAg).Results:  The concentrations of HBcrAg and HBcAg showed significant positive correlation with the HBV‐DNA concentration in both HBV/B (r = 0.79, P < 0.001, and r = 0.77, P < 0.001, respectively) and HBV/C (r = 0.87, P < 0.001, and r = 0.90, P < 0.001, respectively). The cut‐off for a positive HBcAg corresponded to approximately 4.5 log copies/mL, and that for a positive HBcrAg result corresponded to 3–4 log copies/mL. The HBcrAg/HBcAg ratio was higher in patients with HBeAg than in those without HBeAg.Conclusions:  The HBcrAg assay and HBcAg assay are clinically useful in viral quantitation of HBV/B and HBV/C. A combination of these assays would be a valuable tool for analyzing the clinical status of HBV infection.


  • Ethnicity affects the diagnostic validity of alpha‐fetoprotein in hepatocellular carcinoma

    by Amal Gad, Eiji Tanaka, Akihiro Matsumoto, Abd El‐Hamid Serwah, Fawzy Attia, Adel Hassan, Ahmed Sanny, Khalil Ali, Amro Abbas, Abd El‐Raoof El‐Deeb, et al.

    Introduction:  Hepatocellular carcinoma (HCC) is the fourth most common cancer worldwide with a high morbidity and mortality. Alpha‐fetoprotein (AFP) is considered the main tumor marker for HCC diagnosis, but the variation in its diagnostic validity among studies justifies further investigation of the underlying contributing factors. Ethnic difference could be one of the factors that has not been well studied. We aimed at investigating the ethnic difference in AFP validity between Egyptian (representing Arabic North African) and Japanese (representing Asian) for HCC diagnosis.Methods:  Four cohorts with chronic liver diseases (CLD) were studied: 171 Egyptian (65 HCC/106 non‐HCC), and 173 Japanese (45 HCC/128 non‐HCC). Laboratory tests including serum AFP, protein‐induced vitamin K deficiency or absence (PIVKA‐II), alanine aminotransferase (ALT), total bilirubin, platelet count, HBsAg, anti‐HCV, and HCV core antigen were conducted using standard commercially available assays.Results:  A significantly higher sensitivity of AFP in Egyptian in comparison with Japanese for HCC diagnosis (99 vs 67%, P < 0.001) was observed using an AFP cut‐off point of 10 ng/mL, with a comparable specificity (75 vs 82%) While a sensitivity of 98 versus 56%, P < 0.001 and a specificity of 83 versus 89% was found for AFP cut‐off point of 20 ng/mL, respectively. The area under the receiver operating characteristic curve (ROC) was found to be 0.98 (95%CI = 0.969–0.997) for Egyptian and 0.77 (95%CI = 0.686–0.864) for Japanese. The highest sensitivity for the former group occurred at AFP = 20.5 ng/mL and at AFP = 10.2 ng/mL for the latter. Univariate analysis showed no effect for age, sex, underlying liver disease, cirrhosis, Child's class or tumor characteristics (size, pathological grade) on AFP sensitivity, while race significantly contributed to the higher sensitivity among Egyptians in comparison with the Japanese. Using ROC analysis, the AFP cut‐off point for HCC detection in each subgroup of patients with and without each of the risk factors of interest was determined and the subgroups were again subclassified according to AFP positivity (< or ≥ the decided cut‐off point for each group). Logistic regression analysis of those factors combined showed that Egyptian ethnicity with an AFP level >20.5 ng/mL (P = 0.007), older age (>50 years) with an AFP level >26 ng/mL (P = 0.010), and cirrhosis with an AFP level >10.5 ng/mL (P = 0.014) were the independent risk factors for HCC.Conclusion:  There is an ethnic variation in AFP validity between Egyptian and Japanese patients with a significantly lower sensitivity in the latter. Alpha‐fetoprotein should not be the only marker used for screening HCC among Asian Japanese and younger age groups (<50 years) with CLD. In addition, an AFP cut‐off point of 20 ng/mL is recommended when screening patients of Asian origin for HCC.


  • Age‐specific antibody to hepatitis E virus has remained constant during the past 20 years in Japan

    by E. Tanaka, A. Matsumoto, N. Takeda, T.‐C. Li, T. Umemura, K. Yoshizawa, Y. Miyakawa, T. Miyamura, K. Kiyosawa

    We investigated the presence of antibodies to hepatitis E virus (anti-HEV) and hepatitis A virus (anti-HAV) by enzyme immunoassays in sera from 1015 individuals collected in 1974, 1984 and 1994. Age-specific profiles of anti-HEV remained unchanged with a peak at 40-49 years, while those of anti-HAV started to increase in individuals aged 20-29 years in 1974, 30-39 years in 1984 and 40-49 years in 1994. These results suggest that a silent HEV infection has been taking place in the last 20 years or so in Japan, while HAV infection has been terminated at least since 1974.


  • Open Access

    Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma

    by Amal Gad, Eiji Tanaka, Akihiro Matsumoto, Moushira Abd-El Wahab, Abd El-Hamid Serwah, Fawzy Attia, Khalil Ali, Howayda Hassouba, Abd El-Raoof El-Deeb, Tetsuya Ichijyo, et al.

    Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma


  • Factors predisposing to the occurrence of cryoglobulinemia in two cohorts of Egyptian and Japanese patients with chronic hepatitis C infection: Ethnic and genotypic influence

    by Amal Gad, Eiji Tanaka, Akihiro Matsumoto, Abd El‐Hamid Serwah, Khalil Ali, Fathy Makledy, Ahmed El‐Gohary, Koji Orii, Akihiro Ijima, Akinori Rokuhara, et al.

    The association between cryoglobulinemia and hepatitis C virus (HCV) infection has been reported. However, the factors underlying its wide variation of occurrence have not yet been well identified. To investigate this, cryoglobulinemia was studied in four cohorts of Egyptian and Japanese patients. Fifty Egyptian patients with chronic hepatitis C, infected with genotype 4 (the predominant HCV genotype in Egypt), were compared with 50 age‐ and sex‐matched Japanese patients, infected with HCV genotype 1b (the predominant HCV genotype in Japan). Thirty‐two Egyptian and 30 age‐ and sex‐matched Japanese patients with chronic hepatitis B were included as controls. All patients were noncirrhotic. Antinuclear antibody (ANA), immunoglobulins (Ig), and cryoglubulins were assessed. Results showed a significantly higher prevalence of cryoglobulinemia in chronic hepatitis C Japanese genotype 1b (40%) as compared with Egyptian genotype 4 (14%), P = 0.003, while no difference was found between Japanese (17%) and Egyptian chronic hepatitis B controls (13%). Symptomatic cryoglobulinemia was more prevalent in the Japanese than in the Egyptian chronic hepatitis C group (10% vs. 4%), but the difference was not statistically significant. Univariate analysis showed no association between cryoglobulinemia and either age, sex, alanine aminotransferase level, or HCV viral load in Japanese or Egyptian patients, while the mean IgM level was significantly higher in the cryoglobulin‐positive than in the cryoglobulin‐negative chronic hepatitis C patients in each group (P = 0.003 and 0.017, respectively). Cryoglobulinemia was found to be significantly associated with both high IgG level (P = 0.020), and positive ANA (P < 0.001) in Japanese patients with chronic hepatitis C, genotype 1b but not in Egyptians with genotype 4. Multivariate analysis showed that the only factors predisposing to cryoglobulinemia were Japanese ethnicity with HCV genotype1b (P = 0.002, OR = 2.56), high IgM level of >245 mg/dl (P = 0.018, OR = 2.05) and female gender (P = 0.040, OR = 1/0.66). In conclusion, cryoglobulinemia is prevalent in Japanese patients with chronic hepatitis C infected with genotype 1b, but cryoglobulinemia is not common in Egyptians with HCV genotype 4. Although it was not possible to evaluate ethnicity and HCV genotype separately in this study, HCV genotype 1b appears to predispose more to cryoglobulinemia than does genotype 4. Female gender and high serum IgM level were also related. J. Med. Virol. 70:594–599, 2003.


  • Open Access

    Clinical significance of SEN virus infection in patients on maintenance haemodialysis

    by Nobuhiko Kobayashi, Eiji Tanaka, Takeji Umemura, Akihiro Matsumoto, Toshiyo Iijima, Makoto Higuchi, Kazuhiko Hora, Kendo Kiyosawa

    Background. The SEN virus (SENV) has been identified as a putative new hepatitis virus. This study was conducted to clarify the clinical significance of SENV infection in patients on haemodialysis. Methods. A total of 189 patients on maintenance haemodialysis and 60 healthy controls were enrolled. Of the 189 patients, 154 were followed up for 2 years. SENV DNA (genotypes D and H) was measured by means of polymerase chain reaction. Results. SENV infection was significantly (P=0.012) more prevalent in patients on haemodialysis (38%) than in controls (22%). SENV infection was not associated with the amount of transfusion or duration of haemodialysis, while hepatitis C virus (HCV) infection was significantly associated with both of these factors. Elevation of alanine aminotransferase was significantly associated with HCV, but not with SENV viraemia. Of the 154 patients who were followed up, 63 (41%) remained negative, 34 (22%) gained positivity, 28 (18%) lost it and 29 (19%) remained positive for SENV infection. Episodes of alanine aminotransferase elevation were recorded for 3% of the patients who incurred SENV infection and this rate was similar to that observed in patients who were continuously negative for SENV infection (5%). Conclusions. SENV infection was common in patients on haemodialysis. No evidence was obtained that suggested involvement of the hepatitis virus in the pathogenicity of SENV.


  • Clinical significance of T.T. virus infection in maintenance hemodialysis patients of an endemic area for hepatitis C infection

    by Amal Gad, Eiji Tanaka, Koji Orii, Akinori Rokuhara, Zohair Nooman, Abd El-Hamid Serwah, Assem El-Sherif, Mohamed El-Essawy, Kaname Yoshizawa, Kendo Kiyosawa